Hypertrophic Scar,Keloid
Conditions
Interventions
Observation group:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 90 Years
Inclusion criteria
Inclusion criteria: 1. According to clinical manifestations, medical history, etc., diagnosed as having hypertrophic scars/keloids; 2. Planned to undergo 32P radionuclide applicator therapy for hypertrophic scars/keloids; 3. The study participant understands the study protocol and agrees to sign the informed consent form; 4. Blood routine: WBC > 3×10^9/L, Plt > 80×10^9/L, and no severe liver or kidney diseases; 5. The study participant understands the study protocol and agrees to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients requiring surgical excision/laser/drug therapy due to scar volume exceeding 200 cm^2 or height exceeding 4 mm; 2. Those who plan to become pregnant within 1 year or are currently pregnant; 3. Those with acute severe infections and ulcers that may affect treatment efficacy evaluation or increase treatment risks; 4. Those allergic to 32P radionuclide; 5. Those with WBC < 3×10^9/L, Plt < 80×10^9/L, or severe liver and kidney diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate of keloid treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence rate of keloids;Participant satisfaction; | — |
Countries
China
Contacts
Public ContactLi Huanbin
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed